Business Description
Seer, Inc. is a life sciences firm specializing in developing and commercializing advanced technologies designed to unravel the complexities of the proteome. At the core of its offerings is the Proteograph Product Suite, an integrated platform comprising specialized consumables, automated instrumentation, and sophisticated software. This comprehensive solution empowers researchers to conduct advanced proteomic studies across various applications, including therapeutic and diagnostic investigations, as well as clinical trials. The company markets its products exclusively for research applications, serving academic institutions, diverse life sciences and research laboratories, and biopharmaceutical and biotechnology enterprises. Notably, these offerings are intended for non-diagnostic and non-clinical purposes. Seer has established collaborative agreements with entities such as Discovery Life Sciences, LLC, and the Salk Institute for Biological Studies. Originally incorporated in 2017 as Seer Biosciences, Inc., the company adopted its current name, Seer, Inc., in July 2018. Its headquarters are situated in Redwood City, California.
Business History
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): -1.28
Total Equity: $259.31M
Shares: 57,447,580
Total Debt: $21.08M
Cash: $47.29M
EBITDA: -$71.89M
Total Debt: $21.08M
Cash: $47.29M
Revenue: $16.12M
Shares: 57,447,580
Revenue: $16.12M
Revenue: $16.12M
Revenue: $16.12M
Total Equity: $259.31M
Tax Rate: -0.3%
Equity: $259.31M
Total Debt: $21.08M
Cash: $47.29M
Current Liabilities: $15.69M
Long-Term Debt: $21.08M
Total Debt: $21.08M
Total Equity: $259.31M
Shares: 57,447,580
Shares: 57,447,580
CapEx: -$1.80M
Shares: 57,447,580
Stock Price: $1.62
Net Income: -$73.60M
Industry Benchmarks
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
Income Statement (Annual)
Last updated: Jul 5, 2026 4:10am (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $6.4M | $14.7M | $15.2M | $13.9M | $16.1M |
| Cost of Revenue | $6.8M | $14.3M | $13.7M | $7.1M | $8.1M |
| Gross Profit | $-374,000 | $384,000 | $1.4M | $6.8M | $8.0M |
| Operating Expenses | $71.3M | $98.4M | $106.4M | $106.9M | $86.0M |
| Operating Income | -$71.7M | -$98.0M | -$104.9M | -$100.1M | -$78.0M |
| Net Income | -$71.2M | -$93.0M | -$86.3M | -$86.6M | -$73.6M |
| EBITDA | -$67.6M | -$87.1M | -$80.7M | -$80.3M | -$71.9M |
| EPS | $-1.13 | $-1.42 | $-1.35 | $-1.39 | $-1.28 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jul 5, 2026 4:10am (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $232.8M | $53.2M | $32.5M | $40.8M | $47.3M |
| Total Current Assets | $411.7M | $435.0M | $330.5M | $253.3M | $201.5M |
| Total Assets | $539.1M | $487.9M | $436.3M | $366.6M | $296.1M |
| Current Liabilities | $13.4M | $12.6M | $13.2M | $15.3M | $15.7M |
| Long-Term Debt | $0 | $0 | $0 | $0 | $21.1M |
| Total Liabilities | $36.2M | $40.9M | $39.4M | $39.0M | $36.8M |
| Total Equity | $502.9M | $447.0M | $396.9M | $327.6M | $259.3M |
| Retained Earnings | -$126.5M | -$219.5M | -$305.8M | -$392.4M | -$466.0M |
Cash Flow (Annual)
Last updated: Jul 5, 2026 4:10am (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$46.3M | -$60.8M | -$59.1M | -$46.1M | -$44.4M |
| Capital Expenditure | -$6.9M | -$10.3M | -$7.3M | -$3.6M | -$1.8M |
| Free Cash Flow | -$53.3M | -$71.0M | -$66.4M | -$49.7M | -$46.2M |
| Acquisitions (net) | $164.0M | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $-35,000 | $-20,000 | $-13,000 | -$11.8M | -$10.2M |
| Net Change in Cash | -$100.6M | -$179.6M | -$20.7M | $8.3M | $6.5M |
Analyst Estimates (Annual)
Last updated: Jul 5, 2026 4:10am (just now)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$20.9M $20.5M – $21.4M
|
$28.4M $28.2M – $28.6M
|
$36.2M $35.9M – $36.5M
|
$49.3M $48.9M – $49.7M
|
| EBITDA |
-$20.9M -$21.4M – -$20.5M
|
-$28.4M -$28.6M – -$28.2M
|
-$36.2M -$36.5M – -$35.9M
|
-$49.3M -$49.7M – -$48.9M
|
| Net Income |
-$41.9M -$44.5M – -$39.4M
|
-$37.3M -$37.8M – -$36.9M
|
-$31.3M -$31.7M – -$31.0M
|
-$4.0M -$4.1M – -$4.0M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jul 5, 2026 4:10am (just now)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +129.7% | +3.4% | -8.1% | +15.6% |
| Gross Profit Growth | +202.7% | +277.3% | +371.5% | +17.2% |
| Operating Income Growth | -36.7% | -7.0% | +4.6% | +22.1% |
| Net Income Growth | -30.6% | +7.2% | -0.4% | +15.0% |
| EBITDA Growth | -28.8% | +7.3% | +0.5% | +10.5% |
Insider Trading (Recent)
All SEC Form 4 codes
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-05-20 | Horn David R. | S-Sale | 7,303.00 | $1.69 | $12,352 |
| 2026-05-08 | Bazarko Anthony R. | A-Award | 225,000.00 | $1.87 | $420,750 |
| 2026-05-08 | Bazarko Anthony R. | A-Award | 75,000.00 | $0.00 | $0 |
| 2026-05-04 | Bazarko Anthony R. | 0.00 | $0.00 | $0 | |
| 2026-02-18 | Horn David R. | S-Sale | 7,743.00 | $1.99 | $15,447 |
| 2026-02-18 | Farokhzad Omid | S-Sale | 24,385.00 | $1.99 | $48,646 |
| 2026-02-03 | Horn David R. | A-Award | 79,000.00 | $0.00 | $0 |
| 2026-02-03 | Horn David R. | A-Award | 119,000.00 | $1.79 | $213,010 |
| 2026-02-03 | Farokhzad Omid | A-Award | 697,162.00 | $0.00 | $0 |
| 2026-02-03 | Farokhzad Omid | A-Award | 512,000.00 | $1.79 | $916,480 |
| 2025-12-09 | MCGUIRE TERRANCE | C-Conversion | 4,088.00 | $0.00 | $0 |
| 2025-12-09 | MCGUIRE TERRANCE | C-Conversion | 4,088.00 | $0.00 | $0 |
| 2025-12-09 | Farokhzad Omid | C-Conversion | 1,438,057.00 | $0.00 | $0 |
| 2025-12-09 | Farokhzad Omid | C-Conversion | 2,117,138.00 | $0.00 | $0 |
| 2025-12-09 | Farokhzad Omid | C-Conversion | 2,117,138.00 | $0.00 | $0 |
| 2025-11-19 | Horn David R. | S-Sale | 6,797.00 | $1.97 | $13,400 |
| 2025-11-19 | Farokhzad Omid | S-Sale | 33,838.00 | $1.97 | $66,708 |
| 2025-09-02 | Ro Isaac | A-Award | 61,000.00 | $2.04 | $124,440 |
| 2025-09-02 | Ro Isaac | A-Award | 41,000.00 | $0.00 | $0 |
| 2025-09-02 | Ro Isaac | 0.00 | $0.00 | $0 |
Narrative Economics
market-narrative step).